Skip to content

A clinical trial to study the effect of Pathyaputhikadi kashaya and Kankayana gudika in patients with Uterine fibroid

Effect of Pathyaputhikadi kashaya and Kankayana gudika in Uterine fibroid - Nil

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/12/077827
Enrollment
26
Registered
2024-12-09
Start date
Unknown
Completion date
Unknown
Last updated
2025-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: D259- Leiomyoma of uterus, unspecified

Interventions

None listed

Sponsors

Karthika Dev S
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Participants of age group 18-45 years with Uterine fibroids, confirmed by USG having complaints of pain and bleeding during menstruation

Exclusion criteria

Exclusion criteria: Pregnant and lactating women Post menopausal women Hb less than 8 gm% Fibroid size greater than 8 cm Degenerative changes in the uterine fibroid confirmed by USG Known cases of malignancy and genital Tb Known case of uncontrolled Hypertension, Diabetes mellitus Known cases of chronic liver and renal disease and coagulation disorders

Design outcomes

Primary

MeasureTime frame
To assess the effect of Pathyaputhikadi kashaya and Kankayana gudika in pain and bleeding during menstruation associated with Uterine fibroidTimepoint: After 4 th week,8th week and 12th week

Secondary

MeasureTime frame
To assess the effect of Pathyaputhikadi kashaya and Kankayana gudika in pelvic pain and low back ache associated with Uterine fibroid To assess the effect of Pathyaputhikadi kashaya and Kankayana gudika in reducing the size of the fibroidTimepoint: After 1st,2nd and 3rd menstrual cycle

Countries

India

Contacts

Public ContactRajitha R Warriar

Government Ayurveda Medical College

drrajithawarriar@gmail.com9947144562

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026